Incidence of hypomagnesemia in patients with HER2+breast cancer treated with pertuzumab.

被引：0
|
作者：
Shah, Nirja
Daily, Karen Colleen
机构：
[1] Univ Florida, Coll Med, Gainesville, FL USA
[2] Univ Florida, UF Hlth Canc Ctr, Gainesville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12569
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pruritus related to trastuzumab and pertuzumab in HER2+breast cancer patients
    Gu, Stephanie
    Dusza, Stephen
    Quigley, Elizabeth
    Haliasos, Helen
    Markova, Alina
    Marchetti, Michael
    Moy, Andrea P.
    Dang, Chau
    Modi, Shanu
    Lake, Diana
    Noor, Sarah
    Lacouture, Mario E.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 271 - 280
  • [2] Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
    Swain, S. M.
    Schneeweiss, A.
    Gianni, L.
    Gao, J. J.
    Stein, A.
    Waldron-Lynch, M.
    Heeson, S.
    Beattie, M. S.
    Yoo, B.
    Cortes, J.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 761 - 768
  • [3] Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
    Swain, S. M.
    Schneeweiss, A.
    Gianni, L.
    Stein, A.
    McNally, V.
    Heeson, S.
    Portera, C.
    Yoo, B.
    Cortes, J. C.
    Baselga, J.
    CANCER RESEARCH, 2016, 76
  • [4] Effect of additional administration of pertuzumab for the post-treatment in patients with HER2-positive locally advanced/metastatic breast cancer who were previously treated with pertuzumab.
    Kubo, Shinichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Prevalence of hypomagnesemia in patients with HER2-positive breast cancer receiving pertuzumab treatment.
    Proverbs-Singh, Tracy Ann
    Cadoo, Karen Anne
    Torre, Gianna
    Patil, Sujata
    Gucalp, Ayca
    Dang, Chau T.
    Hudis, Clifford A.
    Glezerman, Ilya G.
    Traina, Tiffany A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] COST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAINCO ST-UTILITY ANALYSIS OF NEOADJUVANT CHEMOTHERAPY WITH PERTUZUMAB, TRASTUZUMAB AND DOCETAXEL IN PATIENTS WITH HER2+BREAST CANCER IN SPAIN
    Colomer, R.
    Ciruelos, E.
    De la Haba, J.
    Martin, M.
    De Salas-Cansado, M.
    Munoz-Molina, B.
    Albanell, J.
    VALUE IN HEALTH, 2016, 19 (07) : A740 - A740
  • [7] HER2+breast cancer
    Hicks, David G.
    Kulkarni, Swati
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 129 (02) : 263 - 273
  • [8] Phase I trial of gemcitabine plus trastuzumab and pertuzumab in previously treated metastatic HER2+breast cancer.
    Soliman, Hatem Hussein
    Khambati, Fatema
    Han, Hyo S.
    Ismail-Khan, Roohi
    Loftus, Loretta S.
    Minton, Susan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Cost-effectiveness analysis of adding neoadjuvant chemotherapy with pertuzumab, in patients with HER2+breast cancer in Spain
    Abanell, J.
    Ciruelos, E.
    De la Haba, J.
    Martin, M.
    Munoz-Molina, B.
    De Salas-Cansado, M.
    Colomer, R.
    CANCER RESEARCH, 2017, 77
  • [10] Incidence of hypomagnesemia in a pertuzumab-treated population.
    Thomas, Jonathan
    Armaghani, Avan
    Wang, Yu
    Daily, Karen Colleen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345